Homegrown Ayurvedic nutrition brand Kapiva has raised Rs 83.5 crore (approximately $10 million) in fresh funding, led by OrbiMed Asia. Existing investors 3One4 Capital and Vertex Ventures also participated in the round, contributing Rs 11.96 crore and Rs 19.33 crore, respectively. This funding is part of Kapiva’s Series C round, through which the company aims to raise a total of Rs 250 crore.
The regulatory filings show that Kapiva’s board passed a special resolution to issue 5,62,631 compulsory convertible preference shares as part of the transaction. Additionally, Kapiva has increased its Employee Stock Ownership Plan (ESOP) pool by adding 1,41,500 new stock options, bringing the total ESOP pool to 4,47,741.
With these new funds, Kapiva plans to accelerate its expansion and product development. The brand, which offers a range of Ayurvedic and organic health products targeting issues such as weight loss, digestion, diabetes, and hair fall, has raised over $30 million to date. Key investors include Jetty Ventures, Fireside Ventures, OrbiMed, 3One4 Capital, and others. According to data from TheKredible, Kapiva’s post-allotment valuation stands at around $80 million.
Founded in 2015, Kapiva has experienced significant growth in the direct-to-consumer Ayurvedic space, competing with brands like Upakarma Ayurveda, Dr. Vaidya’s, and Varalife. In the fiscal year ending March 2023, Kapiva saw 87% year-on-year growth, recording revenues of Rs 116.48 crore, though it also reported a loss of Rs 64.5 crore.
Kapiva’s recent funding and its expansion plans underscore its ambition to strengthen its position in the increasingly competitive Ayurveda and wellness market, where it continues to stand out by offering natural, organic solutions tailored to modern health concerns.
